Related Experiment Video
Updated: Mar 26, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
The impact of comorbidities on inpatient Charcot neuroarthropathy cost and utilization
Jonathan M Labovitz1, David W Shofler1, Kevin K Ragothaman1
1College of Podiatric Medicine, Western University of Health Sciences, 309 E Second Street, Pomona, CA 91766.
Insights
Comorbidities significantly increase healthcare costs and length of stay for Charcot neuroarthropathy (CN) patients. Managing these conditions is crucial for reducing inpatient expenses and improving patient outcomes.
Area of Science:
- Diabetic foot complications
- Healthcare economics
- Patient outcomes
Background:
- Charcot neuroarthropathy (CN) is a severe complication of diabetic neuropathy.
- Understanding the economic burden of CN is essential for resource allocation.
- Comorbidities are known to influence healthcare utilization and costs.
Purpose of the Study:
- To assess the impact of comorbidities on inpatient costs and utilization in patients with Charcot neuroarthropathy (CN).
- To compare healthcare costs and length of stay (LOS) between CN and diabetic peripheral neuropathy (DPN) cohorts.
- To identify specific comorbidities that drive increased costs and LOS in CN patients.
Main Methods:
- Retrospective cohort study using California patient discharge data (2009-2012).
- Identified CN and DPN cohorts using ICD-9 codes.
- Compared costs and LOS, adjusting for the number of chronic conditions and Elixhauser comorbidity measures.
Main Results:
- CN patients had 17.2% higher costs and 1.4 days longer LOS than DPN patients.
- Additional chronic conditions explained a significant portion of the cost difference.
- Higher Elixhauser comorbidity scores correlated with increased costs, LOS, and mortality.
- Foot ulcers, infections, osteomyelitis, and depression were associated with significantly higher costs and/or LOS.
Conclusions:
- Systemic and local comorbidities substantially influence the cost, utilization, and inpatient mortality for Charcot foot.
- Effective management of comorbidities is vital for optimizing inpatient care and reducing healthcare expenditures in CN patients.
- Further research into targeted interventions for high-risk comorbidities in CN is warranted.
Aims:
The purpose of this study was to portray the impact of comorbidities on inpatient cost and utilization in Charcot neuroarthropathy (CN) patients.
Methods:
Two cohorts, CN and diabetic peripheral neuropathy (DPN), were identified by ICD-9 codes in the California Office for Statewide Health Planning and Development 2009-2012 public patient discharge files. DPN and CN costs and length of stay (LOS) were compared adjusting for the number of chronic conditions. The impact of the Elixhauser comorbidity measures and other comorbidities on costs and LOS in CN subjects was evaluated.
Results:
CN was associated with 17.2% higher costs and 1.4 days longer LOS compared to DPN alone. Adjusting for 0.71 additional chronic conditions in CN patients accounted for 79.8% of variance and estimated a 13.9% cost difference between cohorts. Subjects averaged 4.5 Elixhauser comorbidities with higher scores corresponding to increased cost, LOS, and inpatient mortality. Other diabetic foot risk factors demonstrated that foot ulcers, foot infections, and osteomyelitis had significantly higher costs. Patients with foot ulcers, osteomyelitis, and depression had significantly increased LOS.
Conclusions:
Systemic and local comorbidities significantly impact the cost, utilization, and inpatient mortality in inpatient management of Charcot foot.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Peripheral Artery Disease IV: Nursing Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease I: Introduction

